Penumbra, Inc. (PEN)

Market Cap	9.18B
Revenue (ttm)	1.16B
Net Income (ttm)	34.55M
Shares Out	38.38M
EPS (ttm)	0.89
PE Ratio	270.13
Forward PE	68.10
Dividend	n/a
Ex-Dividend Date	n/a

Volume	248,864
Open	235.29
Previous Close	237.11
Day's Range	235.29 - 239.52
52-Week Range	148.00 - 277.34
Beta	0.51
Analysts	Buy
Price Target	232.23 (-2.91%)
Earnings Date	Oct 30, 2024

About PEN

Penumbra, Inc., together with its subsidiaries, designs, develops, manufactures, and markets medical devices in the United States and internationally. The company offers peripheral products, including the Indigo System for power aspiration of thrombus in the body; Lightning Flash, a mechanical thrombectomy system; Lightning Bolt 7, an arterial thrombectomy system; and CAT RX. It also provides access products, including guide catheters and the Penumbra distal delivery catheters under the Neuron, Neuron MAX Select, BENCHMARK, BMX96, BMX81, DDC, S...

• Industry: Medical Devices
• Sector: Healthcare
• IPO Date: Sep 18, 2015
• Employees: 4,200
• Stock Exchange: NYSE
• Ticker Symbol: PEN
• Website: https://www.penumbrainc.com

Analyst Forecast

According to 14 analysts, the average rating for PEN stock is "Buy." The 12-month stock price forecast is $232.23, which is a decrease of -2.91% from the latest price.

Price Target

$232.23

(-2.91% downside)

Analyst Consensus: Buy